Lilly, Novo Fall After Trump Touts ‘Much Lower’ Ozempic Price
The article reports that shares of pharmaceutical companies Eli Lilly and Novo Nordisk fell in late trading after President Donald Trump stated that the price of the diabetes drug Ozempic could be lowered to around $150 per month. Ozempic is a blockbuster drug, and its potential price reduction could impact the revenue and profits of the two major pharmaceutical companies. The article suggests that Trump's announcement about the possible price drop led to the decline in the stock prices of Eli Lilly and Novo Nordisk, as investors reacted to the potential impact on the companies' financial performance. The article provides a concise summary of the key events and their potential implications, without delving into unnecessary details or making any biased statements.
Source: For the complete article, please visit the original source link below.
